Company intelligence / Profile preview

METRO

Worcester, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

MetroBiotech’s lead compound, MIB-626 (crystallized NMN), increases NAD+ levels in humans and is in Phase 2 trials for COVID-19, kidney injury, and rare mitochondrial diseases. Early clinical results show pharmacological activity and no dose-limiting toxicities for MIB-725 in Phase 1a; robust preclinical efficacy in diseases of aging. MIB-626 demonstrated NAD+ increases in human blood within one week

Therapeutic areas: NephrologyOphthalmologyInfectious DiseasesNeurologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on METRO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on METRO.

Explore the full profile